Retirement Systems of Alabama boosted its stake in Bio-Rad Laboratories Inc. (NYSE:BIO) by 0.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 26,923 shares of the company’s stock after buying an additional 46 shares during the period. Retirement Systems of Alabama’s holdings in Bio-Rad Laboratories were worth $3,851,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in BIO. Meeder Asset Management Inc. increased its stake in Bio-Rad Laboratories by 10,254.5% in the first quarter. Meeder Asset Management Inc. now owns 1,139 shares of the company’s stock valued at $156,000 after buying an additional 1,128 shares during the period. LS Investment Advisors LLC increased its stake in Bio-Rad Laboratories by 70.1% in the second quarter. LS Investment Advisors LLC now owns 1,388 shares of the company’s stock valued at $199,000 after buying an additional 572 shares during the period. LaSalle Street Capital Management LLC purchased a new stake in Bio-Rad Laboratories during the second quarter valued at about $207,000. Magnetar Financial LLC purchased a new stake in Bio-Rad Laboratories during the first quarter valued at about $245,000. Finally, M&T Bank Corp increased its stake in Bio-Rad Laboratories by 10.6% in the first quarter. M&T Bank Corp now owns 1,872 shares of the company’s stock valued at $256,000 after buying an additional 179 shares during the period. 62.76% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Bio-Rad Laboratories Inc. (NYSE:BIO) traded up 0.04% on Monday, reaching $161.39. 80,784 shares of the company’s stock traded hands. The firm has a market capitalization of $4.75 billion, a P/E ratio of 48.95 and a beta of 0.87. The company’s 50-day moving average is $159.13 and its 200-day moving average is $148.39. Bio-Rad Laboratories Inc. has a 52 week low of $122.03 and a 52 week high of $164.89.
Bio-Rad Laboratories (NYSE:BIO) last posted its earnings results on Wednesday, August 3rd. The company reported $0.61 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.13 by $0.52. The business earned $516.80 million during the quarter, compared to the consensus estimate of $497.80 million. Bio-Rad Laboratories had a return on equity of 3.86% and a net margin of 4.79%. The business’s revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.97 earnings per share. Equities research analysts anticipate that Bio-Rad Laboratories Inc. will post $3.10 earnings per share for the current fiscal year.
BIO has been the topic of several analyst reports. CL King initiated coverage on shares of Bio-Rad Laboratories in a research note on Wednesday, October 12th. They set a “buy” rating and a $180.00 price target on the stock. Jefferies Group raised their price objective on shares of Bio-Rad Laboratories from $200.00 to $225.00 and gave the stock a “buy” rating in a report on Wednesday, September 7th. Finally, Zacks Investment Research raised shares of Bio-Rad Laboratories from a “sell” rating to a “hold” rating in a report on Wednesday, July 6th.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of life science research and clinical diagnostics products. The Company manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.
Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories Inc. (NYSE:BIO).
Receive News & Ratings for Bio-Rad Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.